Disease Progression
IV edaravone may slow disease-progression milestones in ALS
Treatment with IV edaravone for ALS was linked to a slowing of disease-progression milestones compared with no IV edaravone treatment, results of an administrative claims analysis show.
Even with treatment, patients with COPD regularly become frequent exacerbators
BOSTON — Moving from Global Initiative for Chronic Obstructive Lung Disease, or GOLD, group A/B to group E was common among patients starting a new inhaled maintenance medication, according to a presentation at the CHEST Annual Meeting.
Daily dose of oral edaravone for ALS nonsuperior to staggered regimen at 48 weeks
For individuals with ALS, a daily dosing regimen of oral edaravone was nonsuperior to an FDA-approved staggered regimen of the drug plus placebo, according to a poster presented at AANEM.
Blarcamesine slows clinical decline in Alzheimer’s disease
Treatment with oral blarcamesine for older adults with Alzheimer’s disease led to significant slowing of clinical decline compared with placebo at 48 weeks, according to new research presented at CTAD.
Koselugo significantly reduces neurofibromas in ongoing phase 3 study
An oral therapeutic significantly reduced the number of tumors in adults with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas, according to topline results from a phase 3 study.
Analysis of Alzheimer’s pathology in brain cells finds deterioration in two stages
A genetic analysis of postmortem brains from individuals in various stages of Alzheimer’s disease revealed two distinct phases of cell deterioration, according to research published in Nature Neuroscience.
Earlier use of targeted therapies may delay MS disease progression over 5 years
ORLANDO, Fla. — Patients with MS who developed paramagnetic rim lesions declined more rapidly, but implementing disease-modifying therapies earlier could reduce the burden of disease progression, data show.
Disease progression slowed by 80% at 24 months in phase 1/2 studies of HD gene therapy
Interim results of phase 1/2 clinical trials of an investigational gene therapy for Huntington’s disease showed that disease progression slowed by 80% at 24 months, according to the manufacturer.
VIDEO: Antibiotics linked to exacerbation of myasthenia gravis
DENVER — The use of several common antibiotics led to exacerbation of myasthenia gravis in a small cohort of patients, Sanem P. Uysal, MD, said in this Healio video from the American Academy of Neurology annual meeting.
Lysophosphatidic acid receptor 1 antagonist slows time to disease progression in IPF
SAN DIEGO — Taking an oral lysophosphatidic acid receptor 1 antagonist for 26 weeks slowed time to disease progression in idiopathic pulmonary fibrosis, according to a presentation at the American Thoracic Society International Conference.